HP
TLSI icon

Hartree Partners’s TriSalus Life Sciences TLSI Stock Holding History

Hartree Partners’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$16.4M Hold
1,730,000
– – 3.82% 3
2021
Q3 		$17.2M Buy
+1,730,000
New +$16.9M 4.26% 2

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Hartree Partners's TLSI Position: Q4 2021 in Review

Hartree Partners held its TriSalus Life Sciences (TLSI) position steady in Q4 2021 at 1,730,000 shares worth $16.4M. The position accounts for 3.82% of the portfolio, ranked #3.

Hartree Partners first reported a position in TLSI in Q3 2021 and has held it in 2 quarters since. The position peaked at $17.2M in Q3 2021. 68 funds tracked by Wall St. Rank hold TLSI as of Q4 2021.

  • Hartree Partners held 1,730,000 shares of TriSalus Life Sciences worth $16.4M as of Q4 2021.
  • Hartree Partners left its TriSalus Life Sciences share count unchanged in Q4 2021.
  • TriSalus Life Sciences made up 3.82% of Hartree Partners's portfolio in Q4 2021, its #3 holding.
  • Hartree Partners first reported a position in TriSalus Life Sciences in Q3 2021 and has held it in 2 quarters since.
  • Hartree Partners's TriSalus Life Sciences position peaked at $17.2M in Q3 2021.
  • 68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2021.

Based on Hartree Partners's 13F filing for Q4 2021, filed 14 Feb 2022.